The US Drug Enforcement Administration (DEA) had granted GW Pharmaceuticals’ request to completely deschedule its cannabis-derived drug, Epidiolex.

GW Pharma’s CBD extract previously sat in Schedule V, but as of Monday it’s been completely removed from the federal list of controlled substances — a first for a cannabis drug in the 21st century.

See the original article at Leafly